The consequences of these modifications are that IGF-1 LR3 retains the pharmacological activity of IGF-1 as an agonist of the IGF-1 receptor, has very low affinity for the insulin-like growth factor-binding proteins (IGFBPs), and has improved metabolic stability resulting in approximately three times greater potency than IGF-1, with a significantly longer half-life of about 2030 hours relative to IGF-1s half-life of about 1215 hours
GLP-1 drugs, especially injectable versions, can sometimes cause local irritation at the injection site, such as skin discoloration or swelling
As many as 35% of people in the United States are considered to be obese, which makes up for a staggering statistic
Despite the substantial benefits of bariatric metabolic surgery in reducing body mass index (BMI) and improving comorbid conditions such as diabetes mellitus (DM), hypertension (HTN), and hyperlipidemia (HLP), WR, IWL, and other complications can hinder long-term success [4,5,6,7]